ENDRA Life Sciences Inc. — Director's Dealing 2017

May 19, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2017-05-08

Reporting Person: DIGIANDOMENICO ANTHONY (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	39199	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options	$10.01	2020-07-07	Common Stock (3297)		Direct
Warrants to Purchase Common Stock	$20.02	2018-09-04	Common Stock (999)		Direct
Convertible Promissory Note	$1.40	2017-05-12	Common Stock ()		Direct

Footnotes

F1: The principal amount of, and accrued interest on, the Convertible Promissory Note is convertible into shares of Common Stock of the Issuer at a
conversion price of $1.40 per share immediately prior to the consummation of the Issuer's initial public offering.